Evaluation of Surrogate Endpoints in Phase III Randomized Control Trials of Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2025 Mar 13

PMID 40080137

Authors

Ke Jiang

Miaowen Liu

Xiao Zhao

Shutong Wang

Yunyan Ling

Liangliang Qiao

Jianfei Tu

Zhenwei Peng

Affiliations

Soon will be listed here.

Abstract

Purpose: Overall survival (OS) is recommended as a gold standard endpoint but has some limitations. We aimed to finding more effective surrogate endpoints for advanced hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).

Methods: Three online databases were searched for randomized control trials (RCTs) on HCC, published between January 2015 and July 2023, that evaluated ICIs and reported progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and OS. The correlation between the potential surrogate endpoints and OS was evaluated at the trial, arm, and patient levels. The prediction models were validated in single-arm or non-RCTs. Individual data were collected from a real-world (RW) cohort with advanced HCC underwent ICI monotherapy at three tertiary medical centers in China.

Results: Ten RCTs (6023 participants) with 11 comparisons were included. PFS had a moderately significant association with OS (R = 0.50, p = 0.014). ORR, DCR, and OS showed weak correlations. On limiting the analysis to ICI monotherapy studies, the correlations of OS with PFS became stronger (R = 0.85, p = 0.02). The RW cohort also verified that PFS was closely related to OS when patient received with ICI monotherapy.

Conclusion: PFS are recommended as surrogate markers in patients with advanced HCC treated with ICI monotherapy.

References

Upadhaya S, Neftelinov S, Hodge J, Campbell J . Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 2022; 21(7):482-483. DOI: 10.1038/d41573-022-00030-4. View

Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N . Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022; 15(1):111. PMC: 9386972. DOI: 10.1186/s13045-022-01325-0. View

Benson A, DAngelica M, Abbott D, Anaya D, Anders R, Are C . Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(5):541-565. DOI: 10.6004/jnccn.2021.0022. View

Gordan J, Kennedy E, Abou-Alfa G, Beg M, Brower S, Gade T . Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38(36):4317-4345. DOI: 10.1200/JCO.20.02672. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Chiou V, Burotto M . Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015; 33(31):3541-3. PMC: 4622096. DOI: 10.1200/JCO.2015.61.6870. View

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

Zhao F . Surrogate End Points and Their Validation in Oncology Clinical Trials. J Clin Oncol. 2016; 34(13):1436-7. DOI: 10.1200/JCO.2016.66.4581. View

Lee D, Jang M, Lee K, Cho E, Lee J, Yu S . TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. Br J Cancer. 2016; 115(10):1201-1205. PMC: 5104893. DOI: 10.1038/bjc.2016.322. View

10.

Llovet J, Montal R, Villanueva A . Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol. 2019; 70(6):1262-1277. DOI: 10.1016/j.jhep.2019.01.028. View

11.

Terashima T, Yamashita T, Toyama T, Arai K, Kawaguchi K, Kitamura K . Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Liver Cancer. 2019; 8(2):130-139. PMC: 6465721. DOI: 10.1159/000489505. View

12.

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

13.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

14.

Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C . Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021; 375:e066381. PMC: 8689398. DOI: 10.1136/bmj-2021-066381. View

15.

Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H . Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2019; 38(3):193-202. DOI: 10.1200/JCO.19.01307. View

16.

Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo B . Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2022; 41(7):1434-1443. PMC: 9995104. DOI: 10.1200/JCO.22.00620. View

17.

Yau T, Park J, Finn R, Cheng A, Mathurin P, Edeline J . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021; 23(1):77-90. DOI: 10.1016/S1470-2045(21)00604-5. View

18.

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

19.

Kelley R, Rimassa L, Cheng A, Kaseb A, Qin S, Zhu A . Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23(8):995-1008. DOI: 10.1016/S1470-2045(22)00326-6. View

20.

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C . Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021; 22(7):977-990. DOI: 10.1016/S1470-2045(21)00252-7. View